It will be used as a potential cure for the blood disorder beta thalassaemia. Stem cells will be reprogrammed to correct the condition, sparing patients from frequent blood transfusions.
The therapy relies on Crispr technology to disable the genetic switch that causes beta thalassaemia, allowing the body to produce fetal haemoglobin instead of the adult form affected by the disorder.
[
Collection
]
[
|
...
]